Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy; Alzheimer's Disease

Treatments: Drug: BMS-708163

Study type: Interventional

Funder types: Industry

Identifiers

NCT00901498

CN156-004

Details and patient eligibility

About

The purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the Phase 2 study.

Enrollment: 36 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Young healthy male subjects

Exclusion criteria

• Women

Trial design

36 participants in 5 patient groups

Treatment A (Reference)

Experimental group

Treatment:

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Treatment B

Active Comparator group

Treatment:

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Treatment C

Active Comparator group

Treatment:

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Treatment D

Active Comparator group

Treatment:

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Treatment E

Active Comparator group

Treatment:

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163

Drug: BMS-708163